References

1. Hamman JH, Enslin GM, Kotze AF. Oral delivery of peptide drugs-barriers and developments. Drug Deliv 2005; 19:165-177.

2. Wender PA, Mitchell DJ, Pattabiraman K, et al. The design, synthesis, and evaluation of molecules that enable or enhance cellular uptake: peptoid molecular transporters. Proc Natl Acad Sci U S A 2000; 97:13003-13008.

3. Rothbard JB, Garlington S, Lin Q, et al. Conjugation of arginine digomers to cyclosporin A facilitates topical delivery and inhibition of inflammation. Nat Med 2000; 6:1253-1257.

4. Hole JW. Human Anatomy and Physiology. 2nd ed. Dubuque, Iowa: Wm. C. Brown Company, 1981:414, 439.

5. Leonhardt H. Color Atlas/Text of Human Anatomy. Vol 2. 4th ed. New York: Thieme Medical Publishers, 1993:213.

6. Fujita T, Tanaka K, Tokunaga J. SEM Atlas of Cells and Tissues. New York: Igaku-Shoin, 1981:122, 123, 129, 135.

7. Trier JS. Morphology of the epithelium of the small intestine. In: Code CF, ed. Handbook of Physiology, Section 6, Alimentary Canal, Vol 3, Intestinal Absorption. Washington, D.C: American Physiological Society, 1968:1133.

8. Tortora GJ, Anagnostakos NP. Principles of Anatomy and Physiology. 6th ed. New York: Harper and Row, 1990:770.

9. Gershkovich P, Qadri B, Yacovan A, et al. Different impacts of intestinal lymphatic transport on the oral bioavailability of structurally similar synthetic lipophilic cannabinoids: dexanabinol and PRS-2111,120. Eur J Pharm Sci 2007; 31:298-305.

10. Fordtran JS, Rector FC Jr., Ewton MF, et al. Permeability characteristics of the human small intestine. J Clin Invest 1965; 44:1935-1944.

11. Danielli JF, Davson H. A contribution to the theory of permeability of thin films. J Cell Comp Physiol 1935; 5:495-508.

12. Davson H, Danieli JF. The Permeability of Natural Membranes. 2nd ed. New York: Cambridge University Press, 1952.

13. Junqueira LC, Carneiro J, Kelley RO. Basic Histology. 6th ed. East Norwalk, CT: Appleton and Lange, 1989:32.

14. Hober R, Hober J. Experiments on the absorption of organic solutes in the small intestine of rats. J Cell Comp Physiol 1937; 10:401-422.

15. Schanker LS. Absorption of drugs from the rat colon. J Pharmacol Exp Ther 1959; 126:283290.

16. Wright EM, Diamond JM. Patterns of non-electrolyte permeability. Proc R Soc Lond B Biol Sci 1969; 172:203-225.

17. Wright EM, Diamond JM. Patterns of non-electrolyte permeability. Proc R Soc Lond B Biol Sci 1969; 172:227-271.

18. Diamond JM, Wright EM. Molecular forces governing nonelectrolyte permeation through cell membranes. Proc R Soc Lond B Biol Sci 1969; 172:273-316.

19. vande Waterbeemd H, Lennernas H, Artursson P, eds. Drug Bioavailability—Estimation of Solubility, Permeability, Absorption and Bioavailability, Weinheim, Germany: Wiley-VCH, 2003.

20. Lipinski CA, Lombardo F, Dominy BW, et al. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Deliv Rev 1997; 23:3-25.

21. Faulkner JM. Nicotine posioning by absorption through the skin. J Am Med Assoc 1933; 100:1664-1665.

22. Travell J. The influence of the hydrogen ion concentration on the absorption of alkaloids from the stomach. J Pharmacol Exp Ther 1940; 69:21-33.

23. Jacobs MH. Some aspects of cell permeability to weak electrolytes. Cold Spring Harbor Symp Quant Biol 1940; 8:30-399.

24. Shore PA, Brodie BB, Hogben CAM. The gastric secretion of drugs: a pH partition hypothesis. J Pharmacol Exp Ther 1957; 119:361-369.

25. Schanker LS, Shore PA, Brodie BB, et al. Absorption of drugs from the stomach. I. The rat. J Pharmacol Exp Ther 1957; 120:528-539.

26. Hogben CAM, Schanker LA, Tocco DJ, et al. Absorption of drugs from the stomach. II. The human. J Pharmacol Exp Ther 1957; 120:540-545.

27. Schanker LS, Tocco DJ, Brodie BB, et al. Absorption of drugs from the rat small intestine. J Pharmacol Exp Ther 1958; 123:81-87.

28. Hogben CAM, Tocco DJ, Brodie BB, et al. On the mechanism of intestinal absorption of drugs. J Pharmacol Exp Ther 1959; 125:275-282.

29. Doluisio JT, Billups NF, Dittert LW, et al. Drug absorption. I. An in situ rat gut technique yielding realistic absorption rates. J Pharm Sci 1969; 58:1196-1200.

30. Benet LZ. Biopharmaceutics as a basis fro the design of drug products. In: Ariens EJ, ed., Drug Design. Vol 4. New York: Academic Press, 1973:26-28.

31. Riggs DS. The Mathematical Approach to Physiological Problems. Baltimore: Williams & Wilkins, 1963:181-185.

32. Flynn GL, Yalkowsky SK, Roseman TJ. Mass transport phenomena and models: theoretical concepts. J Pharm Sci 1974; 63:479-510.

33. Mayersohn M. Drug absorption. J Clin Pharmacol 1987; 27:634-638.

34. He Y-L, Murby S, Warhurst G, et al. Species differences in size discrimination in the paracellular pathway reflected by oral bioavailability of poly (ethylene glycol) and D-peptides. J Pharm Sci 1998; 87:626-633.

35. Johnson PH, Frank D, Costantino HR. Discovery of tight junction modulators: significance fro drug development and delivery. Drug Discov Today 2008; 13:261-267.

36. Evered DF, Randall HG. The absorption of amino acid derivatives of nitrogen mustard from rat intestine in vitro. Biochem Pharmacol 1962; 11:371-376.

Levy G, Jusko WJ. Factors affecting the absorption of riboflavin in man. J Pharm Sci 1966; 55: 285-289.

Mayersohn M. Ascorbic acid absorption in man-pharmacokinetic implications. Eur J Pharmacol 1972; 19:140-142.

Gillespie NG, Mena I, Cotzias GC, et al. Diets affecting treatment of Parkinsonism with levodopa. J Am Diet Assoc 1973; 62:525-528.

Wade DN, Mearrick PT, Morris JL. Active transport of l-dopa in the intestine. Nature 1973; 242: 463-465.

van Woert MH. Phenylalanine and tyrosine metabolism in Parkinson's disease treated with levodopa. Clin Pharmacol Ther 1971; 12:368-375.

Lennernas H, Nilsson D, Aquilonius S-M, et al. The effect of l-leucine on the absorption of levodopa, studied by regional jejunal perfusion in man. Br J Clin Pharmacol 1993; 35: 343-250.

Zimmerman J. Methotrexate transport in the human intestine. Biochem Pharmacol 1992; 43: 2377-2383.

Westphal J-F, Trouvin J-H, Deslandes A, et al. Nifedipine enhances amoxicillin absorption kinetics and bioavailability in human. J Pharmacol Exp Ther 1990; 255:312-317. Duverne C, Bouten A, Deslandes A, et al. Modification of cifixime bioavailability by nifedipine in humans: involvement of the dipeptide carrier system. Antimirob Agents Chemother 1992; 36:2462-2467.

Stewart BH, Kugler AR, Thompson PR, et al. A saturable transport mechanism in the intestinal absorption of gabapentin is the underlying cause of the lack of proportionality between increasing dose and drug levels in plasma. Pharm Res 1993; 10:276-281. Gottesman II, Pastan I. Biochemistry of multidrug resistance mediated by the multidrug transporter. Annu Rev Biochem 1993; 62:385-427.

Tanigawara Y. Role of p-glycoprotein in drug disposition. Ther Drug Monit 2000; 22: 137-140.

Asperen JV, Tellingen OV, Beijnen JH. The pharmacological role of p-glycoprotein in the intestinal epithelium. Pharmacol Res 1998; 37:429-435.

Zhang Y, Benet LZ. The gut as a barrier to drug absorption-combined role of cytochrome P450 3A and P-glycoprotein. Clin Pharmacokin 2001; 40:159-168.

Mizuno N, Niwa T, Yotsumoto Y, et al. Impact of drug transporter studies on drug discovery and development. Pharmacol Rev 2003; 55:425-461.

Aszalos A. Drug-drug interactions affected by the transporter protein P-glycoprotein (ABCB1, MDR1). I. Preclinical aspects. Drug Discov Today 2007; 12:833-837.

Aszalos A. Drug-drug interactions affected by the transporter protein P-glycoprotein (ABCB1, MDR1). II.Clinical aspects. Drug Discov Today 2007; 12:838-843.

Szakacs G, Varadi A, Ozvegy-Laczka C, et al. The role of ABC transporters in drug absorption, distribution, metabolism, excretion and toxicity (ADME-Tox). Drug Discov Today 2008; 13:379-393.

Wacher J, Salphati L, Benet LZ. Active secretion and enterocyte drug metabolism barriers to drug absorption. Adv Drug Deliv Rev 1996; 20:99-112.

Sparreboom A, van Asperen J, Mayer U, et al. Limited oral bioavailability of taxol and active epithelial secretion of paclitaxel (Taxol) caused by p-glycoprotein in the intestine. Proc Natl Acad Sci U S A 1997; 94:2031-2035.

Westphal K, Weinbrenner A, Giessmann T, et al. Oral bioavailability of digoxin is enhanced by talinolol: evidence for involvement of intestinal p-glycoprotein. Clin Pharmacol Ther 2000; 68: 6-12.

Dressman JB, Amidon GL, Reppas C, et al. Dissolution testing as a prognostic tool for oral drug absorption: immediate release dosage forms. Pharm Res 1998; 15:11-22.

Bates TR, Young JM, Wu CM, et al. pH-dependent dissolution rate of nitrofurantoin from commercial suspensions, tablets and capsules. J Pharm Sci 1974; 63:643-645.

Levy G, Sahli BA. Comparison of the gastrointestinal absorption of aluminum acetylsalicylate and acetylsalicylic acid in man. J Pharm Sci 1962; 51:58-62.

61. Levy G, Procknal JA. Unusual dissolution behavior due to film formation. J Pharm Sci 1962; 51:294.

62. Blezek CE, Lach JL, Guillory JK. Some dissolution aspects of ferrous sulfate tablets. Am J Hosp Pharm 1970; 27:533-539.

63. Crounse RG. Human Pharmacology of griseofulvin. The effect of fat intake on gastrointestinal absorption. J Invest Dermatol 1961; 37:529-533.

64. Kraml M, Dubuc J, Beall D. Gastrointestinal absorption of griseofulvin. I. Effect of particle size, addition of surfactants and corn oil on the level of griseofulvin in the serum of rats. Can J Biochem Physiol 1962; 40:1449-1451.

65. Moes AJ. Gastroretentive dosage forms. Crit Rev Ther Drug Carrier Syst 1993; 10:143-195.

66. Minami H, McCallum RW. The physiology and pathophysiology of gastric emptying in humans. Gastroenterol 1984; 86:1592-1610.

67. Renwick AG, Ahsan CH, Challenor VF, et al. The influence of posture on the pharmacokinetics of orally administered nifedipine. Br J Clin Pharmacol 1992; 34:332-336.

68. Hopkins A. The pattern of gastric emptying: a new view of old results J Physiol 1966; 182: 144-149.

69. Elashoff JD, Reedy TJ, Meyer JH. Analysis of gastric emptying data. Gastroenterol 1982; 83: 1306-1312.

70. Blythe RH, Grass GM, MacDonnell DR. The formulation and evaluation of enteric coated aspirin tablets. Am J Pharm 1959; 131:206-216.

71. Alpsten M, Bogentoft C, Ekenved G, et al. Gastric emptying and absorption of acetylsalicylic acid administered as enteric-coated micro-granules. Eur J Clin Pharmacol 1982; 22:57-61.

72. Welling P. Effects of food on drug absorption. Annu Rev Nutr 1996; 16:383-415.

73. Fleisher D, Li C, Zhou Y, et al. Drug, meal and formulation interactions influencing drug absorption after oral administration. Clin Pharmacokinet 1999; 36:233-254.

74. Charman WN, Porter CJH, Mithani S, et al. Physicochemical and physiological mechanisms for the effects of food on drug absorption: the role of lipids and pH. J Pharm Sci 1997; 86:269-282.

75. Jones HM, Parrott N, Ohlenbusch G, et al. Predicting pharmacokinetic food effects using biorelevant solubility media and physiologically based modeling. Clin Pharmacokinet 2006; 45: 1213-1226.

76. Gu C-H, Li H, Levons J, et al. Predicting effect of food on extent of drug absorption based on physicochemical properties. Pharm Res 2007; 24:1118-1130.

77. Hendeles L, Weinberger M, Milavetz G, et al. Food-induced 'dose-dumping' from a once-a-day theophylline product as a cause of theophylline toxicity. Chest 1985; 87:758-765.

78. Gai MN, Isla A, Andonaegui MT, et al. Evaluation of the effect of 3 different diets on the bioavailability of 2 sustained release theophylline matrix tablets. Int J Clin Pharmacol Ther 1997; 35:565-571.

79. Wu C-Y, Benet LZ. Predicting drug disposition via application of BCS: transport/absorption/ elimination interplay and development of a biopharmaceutical drug disposition classification system. Pharm Res 2005; 22:11-23.

80. Custodio JM, Wu C-Y, Benet LZ. Predicting drug disposition, absorption/elimination/ transporter interplay and the role of food on drug absorption. Adv Drug Deliv Rev 2008; 60: 717-733.

81. Singh BN. A quantitative approach to probe the dependence and correlation of food-effect with aqueous solubility, dose/solubility ratio, and partition coefficient (log D) for orally active drugs administered as immediate-release formulations. Drug Dev Res 2005; 65:55-75.

82. Bates TR, Sequeira JA, Tembo AV. Effect of food on nitrofurantoin absorption. Clin Pharmacol Ther 1974; 16:63-68.

83. Rosenberg HA, Bates TR. The influence of food on nitrofurantoin bioavailability. Clin Pharmacol Ther 1976; 20:227-232.

84. Yung S, Mayersohn M, Robinson JB. Ascorbic acid absorption in man: influence of divided dose and food. Life Sci 1981; 28:2505-2511.

85. Meuhlberger CW. The physiological action of alcohol. J Am Med Assoc 1958; 167: 1842-1845.

86. Horowitz M, Maddox A, Bochner M, et al. Relationships between gastric emptying of solid and caloric liquid meals and alcohol absorption. Am J Physiol 1989; 257:G291-G298.

87. Jones AW, Jonsson KA, Kechagias S. Effect of high-fat, high-protein, and high-carbohydrate meals on the pharmacokinetics of a small dose of ethanol. Br J Clin Pharmacol 1997; 44: 521-526.

88. Fermaglich J, O'Doherty S. Effect of gastric motility on levodopa. Dis Nerv Syst 1972; 33:624-625.

89. Heading RC, Nimmo J, Prescott LF, et al. The dependence of paracetamol absorption on the rate of gastric emptying. Br J Pharmacol 1973; 47:415-421.

90. Prescott LF, Nimmo WS, Heading RC. Drug absorption interactions. In: Grahame-Smith DG, ed. Drug Interactions. Baltimore: Macmillan, 1977:45.

91. Channer KS, Virjee J. Effect of posture and drink volume on the swallowing of capsules. Br Med J 1982; 285:1702.

92. Hey H, Jorgenson F, Sorensen K, et al. Oesophageal transit of six commonly used tablets and capsules. Br Med J 1982; 285:171-179.

93. Channer KS, Roberts CJC. Effect of delayed esophageal transit on acetaminophen absorption. Clin Pharmacol Ther 1985; 37:72-76.

94. Davis SS, Hardy JG, Fara JW. Transit of pharmaceutical dosage forms through the small intestine. Gut 1986; 27:886-892.

95. Madsen JL. Effects of gender, age, and body mass index on gastrointestinal transit times. Dig Dis Sci 1992; 37:1548-1553.

96. Price JMC, Davis SS, Wilding IR. The effect of fibre on gastrointestinal transit times in vegetarians and omnivores. Int J Pharm 1991; 76:123-141.

97. Pirk F. Changes in the motility of the small intestine in digestive disorders. Gut 1967; 8: 486-490.

98. Guyton AC. Basic Human Physiology: Normal Functions and Mechanisms of Disease. Philadelphia: W B Saunders, 1971:428.

99. Parry E, Shields R, Turnbull AC. Transit time in the small intestine in pregnancy. J Obstet Gynaecol 1970; 77:900-901.

100. Metcalf AM, Phillips SF, Zinsmeister AR, et al. Simplified assessment of segmental colonic transit. Gastroenterology 1987; 92:40-47.

101. Watts PJ, Barrow L, Steed KP, et al. The transit rate of different sized model dosage forms through the human colon and the effects of a lactulose-induced catharsis. Int J Pharm 1992; 87: 215-221.

102. Akin DA, Davis SS, Sparrow RA, et al. Colonic transit of different sized tablets in healthy subjects. J Control Release 1993; 23:147-156.

103. Price JMC, Davis SS, Sparrow RA, et al. The effect of meal composition on the gastrocolonic response: implications for drug delivery to the colon. Pharm Res 1993; 10:722-726.

104. McDougall CJ, Wong R, Scudera P, et al. Colonic mucosal pH in humans. Dig Dis Sci 1993; 38: 542-545.

105. Friend DR. Colon-specific drug delivery. Adv Drug Deliv Rev 1991; 7:149-199.

106. Wilding I. Site-specific drug delivery in the gastrointestinal tract. Crit Rev Ther Drug Carrier Syst 2000; 17:557-620.

107. Antonin KH, Saano V, Bleck P, et al. Colonic absorption of human calcitonin in man. Clin Sci 1992; 83:627-631.

108. Williams MF, Dukes GF, Heizer W, et al. Influence of gastrointestinal site of drug delivery on the absorption characteristics of ranitidine. Pharm Res 1992; 9:1190-1194.

109. Chan KKH, Buch A, Glazer RD, et al. Site-differential gastrointestinal absorption of benazepril hydrochloride in health volunteers. Pharm Res 1994; 11:432-437.

110. d'Agay-Abensour L, Fjellestad-Paulsen A, Hoglund P, et al. Absolute bioavailability of an aqueous solution of 1-deamino-8-D-arginine vasopressin from different regions of the gastrointestinal tract in man. Eur J Clin Pharmacol 1993; 44:473-476.

111. Warner PE, Brouwer KLR, Hussey EK, et al. Sumatriptan absorption from different regions of the human gastrointestinal tract. Pharm Res 1995; 12:138-143.

112. De Boer AG, Moolenaar F, de Leede LGJ, et al. Rectal drug administration: clinical pharmacokinetic considerations. Clin Pharmacokinet 1982; 7:285-311.

113. Winne D. Formal kinetics of water and solute absorption with regard to intestinal blood flow. J Theor Biol 1970; 2:1-18.

114. Winne D, Remischovsky J. Intestinal blood flow and absorption of nondissociable substances. J Pharm Pharmacol 1970; 22:640-641.

115. Crouthamel WG, Diamond L, Dittert LW, et al. Drug absorption. VII. Influence of mesenteric blood flow on intestinal drug absorption in dogs. J Pharm Sci 1975; 64:664-671.

116. Rowland M, Riegelman S, Harris PA, et al. Absorption kinetics of aspirin in man following oral administration of an aqueous solution. J Pharm Sci 1972; 61:379-385.

117. Kruger-Thiemer E. Pharmacokinetics and dose-concentration relationships. In: Ariens EJ, ed. Physico-Chemical Aspects of Drug Action. Elmsford, NY: Pergamon Press, 1968:63-113.

118. Oliver GC, Tazman R, Frederickson R. Influence of congestive heart failure on digoxin level. In: Storstein O, ed. Symposium on Digitalis. Oslo: Gyldendal Norsk Forlag, 1973:336-347.

119. Benowitz NL. Effects of cardiac disease on pharmacokinetics: pathophysiologic considerations. In: Benet LZ, Massoud N, Gainbertoglio JG, eds. Pharmacokinetics Basis for Drug Treatment. New York: Raven Press, 1984:89-103.

120. Price KE, Zolli Z Jr., Atkinson JC, et al. Antibiotic inhibitors. I. The effect of certain milk constituents. Antibiot Chemother 1957; 7:672-688.

121. Price KE, Zolli Z Jr., Atkinson JC, et al. Antibiotic inhibitors. II. Studies on the inhibitory action of selected divalent cations for oxytetracyctine. Antibiot Chemother 1957; 7:689-701.

122. Scheiner J, Altemeier WA. Experimental study of factors inhibiting absorption and effective therapeutic levels of declomycin. Surg Gynecol Obstet 1962; 114:9-14.

123. Neuvonen PJ, Turakka H. Inhibitory effect of various iron salts on the absorption of tetracycline in man. Eur J Clin Pharmacol 1974; 7:357-360.

124. Riegelman S, Crowell WJ. The kinetics of rectal absorption. II. The absorption of anions. J Am Pharm Assoc (Scientific Edition) 1958; 47:123-127.

125. Riegelman S, Crowell WJ. The kinetics of rectal absorption. III. The absorption of undissociated molecules. J Am Pharm Assoc (Scientific Edition) 1958; 47:127-133.

126. Kakemi K, Arita T, Muranishi S. Absorption and excretion of drugs. XXVII. Effect of nonionic surface-active agents on rectal absorption of sulfonamides. Chem Pharm Bull (Tokyo) 1965; 13:976-985.

127. Sorby DL. Effect of adsorbents on drug absorption. I. Modification of promazine absorption by activated attapulgite and activated charcoal. J Pharm Sci 1965; 54:677-683.

128. Wagner JG. Design and data analysis of biopharmaceutical studies in man. Can J Pharm Sci 1966; 1:55-68.

129. Abruzzo CW, Macasieb T, Weinfeld R, et al. Changes in the oral absorption characteristics in man of dipotassium clorasepate at normal and elevated gastric pH. J Pharmacokinet Biopharm 1977; 5:377-390.

130. Galetin A, Hinton LK, Burt H, et al. Maximal inhibition of intestinal first-pass metabolism as a pragmatic indicator of intestinal contribution to the drug-drug interactions for CYP3A4 cleared drugs. Curr Drug Metab 2007; 8:685-693.

131. Rivera-Calimlim L, Dujovne CA, Morgan JP, et al. Absorption and metabolism of l-dopa by the human stomach. Eur J Clin Invest 1971; 1:313-320.

132. Fleckenstein L, Mundy GR, Horovitz RA, et al. Sodium salicylamide: relative bioavailability and sujective effects. Clin Pharmacol Ther 1976; 19:451-458.

133. Levy G, Matsuzawa T. Pharmacokinetics of salicylamide in man. J Pharmacol Ther 1967; 156: 285-293.

134. Frezza M, Di Padova C, Pozzato G, et al. High blood alcohol levels in women: the rold of decreased gastric alcohol dehydrogenase and first-pass metabolism. N Engl J Med 1990; 322: 95-99.

135. Seitz HK, Egerer G, Simanowski UA, et al. Human gastric alcohol dehydrogenase activity: effect of age, sex and alcoholism. Gut 1993; 34:1433-1437.

Bailey DG, Spence JD, Munoz C, et al. Interaction of citrus juices with felodipine and nifedipine. Lancet 1991; 337:268-269.

Hall SD, Thummel KE, Watkins PB, et al. Molecular and physical mechanisms of first-pass extraction. Drug Metab Dispos 1999; 27:161-166.

Bailey DG, Arnold JMO, Spence JD. Inhibitors in the diet: grapefruit juice-drug interactions. In: Levy RH, Thummel KE, Trager WE, et al., eds Metabolic Drug Interactions: New York: Lippincott Williams & Wilkins, 2000:661-667.

Schmeidlin-Ren P, Edwards DJ, Fitzsimmons ME, et al. Mechanisms of enhanced oral availability of CYP3A4 substrates by grapefruit constituents: decreased enterocyte CYP3A4 concentration and mechanism-based inactivation by furanocoumarins. Drug Metab Dispos 1997; 25:1228-1233.

Dresser GK, Bailey DG, Carruthers SG. Grapefruit juice-felodipine interaction in the elderly. Clin Pharmacol Ther 2000; 68:28-34.

Durr D, Stieger B, Kullak-Ublick GA, et al. St. John's wort induces intestinal p-glycoprotein/ MDR1 and intestinal and hepatic CYP3A45. Clin Pharmacol Ther 2000; 68:598-604. Smith RL. The role of the gut flora in the conversion of inactive compounds to active metabolites. In: Aldridge WN, ed. A Symposium on Mechanisms of Toxicity. New York: Macmillan, 1971:228-244.

Kramer PA, Chapron DJ, Benson J, et al. Tetracycline absorption in elderly patients with achlorhydria. Clin Pharmacol Ther 1978; 23:467-472.

Ochs HR, Greenblatt DJ, Dengler HJ. Absorption of oral tetracycline in patients with Billroth-II gastrectomy. J Pharmacokinet Biopharm 1978; 6:295-303.

Levy G, MacGillivray MH, Procknal JA. Riboflavin absorption in children with thyroid disorders. Pediatrics 1972; 50:896-900.

Prescott LF. Gastrointestinal absorption of drugs. Med Clin N Am 1974; 58:907-916. Jusko WJ, Conti DR, Molson A, et al. Digoxin absorption from tablets and elixir: the effect of radiation-induced malabsorption. JAMA 1974; 230:1554-1555.

Sokol GH, Greenblatt DJ, Lloyd BL, et al. Effect of abdominal radiation therapy on drug absorption in humans. J Clin Pharmacol 1978; 18: 388-396.

Heizer WD, Smith TW, Goldfinger SE. Absorption of digoxin in patients with malabsorption syndromes. N Engl J Med 1971; 285:257-259.

Davis AE, Pirola RC. Absorption of phenoxymethyl penicillin in patients with steatorrhea. Austrelas Ann Med 1968; 17:63-65.

Nelson JD, Shelton S, Kusmiesz HT, et al. Absorption of ampicillin and nalidixic acid in infants and children with acute shigellosis. Clin Pharmacol Ther 1972; 13:879-886. Severijnen R, Bayat N, Bakker H, et al. Enteral drug absorption in patients with short small bowel. Clin Pharmcokinet 2004; 43:951-962.

Kampmann JP, Klein H, Lumholtz B, et al. Ampicillin and propylthiouracil pharmacokinetics in intestinal bypass patients followed up to a year after operation. Clin Pharmacokinet 1984; 9: 168-176.

Jusko WJ, Khanna N, Levy G, et al. Riboflavin absorption and excretion in the neonate. Pediatrics 1970; 45:945-949.

Mayersohn M. Special pharmacokinetic considerations in the elderly. In: Evans WE, Schentag JJ, Jusko WJ, eds. Applied Pharmacokinetics: Principles of Therapeutic Drug Monitoring. 3rd ed. Vancouver, WA: Applied Therapeutics, 1992:9.1-9.43.

Mayersohn M. Pharmacokinetics in the elderly. Environ Health Perspect 1994; 102(suppl 11): 119-124.

Mayersohn M. The "xylose test" to assess gastrointestinal absorption in the elderly: a pharmacokinetic evaluation of the literature. J Gerontol 1982; 37:300-305. Johnson SL, Mayersohn M, Conrad KA. Gastrointestinal absorption as a function of age: xylose absorption in healthy adult subjects. Clin Pharmacol Ther 1985; 38:331-335. Russell TL, Berardi RR, Barnett JL, et al. pH-related changes in the absorption of dipyridamole in the elderly. Pharm Res 1994; 11:136-143.

Essentials of Human Physiology

Essentials of Human Physiology

This ebook provides an introductory explanation of the workings of the human body, with an effort to draw connections between the body systems and explain their interdependencies. A framework for the book is homeostasis and how the body maintains balance within each system. This is intended as a first introduction to physiology for a college-level course.

Get My Free Ebook


Post a comment